Provided by Tiger Trade Technology Pte. Ltd.

Disc Medicine

78.65
-1.3800-1.72%
Post-market: 78.660.0142+0.02%16:10 EDT
Volume:882.04K
Turnover:69.21M
Market Cap:3.02B
PE:-11.99
High:80.53
Open:79.19
Low:77.50
Close:80.03
52wk High:99.50
52wk Low:40.00
Shares:38.39M
Float Shares:32.95M
Volume Ratio:2.03
T/O Rate:2.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.5619
EPS(LYR):-6.0116
ROE:-39.08%
ROA:-23.96%
PB:4.69
PE(LYR):-13.08

Loading ...

Disc Medicine to Present Initial Phase 2 Restore-PV Data for DISC-3405 in Polycythemia Vera at SOHO 2026

Reuters
·
36 mins ago

Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

GlobeNewswire
·
37 mins ago

Disc Medicine COO Jonathan Yen-Wen Yu Disposes of 9,096 Common Shares Worth $755,192.83

Reuters
·
Aug 27

Disc Medicine CEO John D. Quisel Disposes of USD 2.63 Million in Common Shares

Reuters
·
Aug 19

Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says

MT Newswires Live
·
Aug 17

Morgan Stanley Adjusts Price Target on Disc Medicine to $90 From $85, Keeps Overweight Rating

MT Newswires Live
·
Aug 17

Disc Medicine COO Jonathan Yu Reports Sale of 804 Common Shares Worth $66,451.57

Reuters
·
Aug 15

Disc Medicine (IRON) Gets a Buy from Wedbush

TIPRANKS
·
Aug 11

H.C. Wainwright Sticks to Its Buy Rating for Disc Medicine (IRON)

TIPRANKS
·
Aug 10

Disc Medicine Chief Legal Officer Rahul Khara Disposes of 5,000 Common Shares for $400,000

Reuters
·
Aug 08

Analysts Are Bullish on Top Healthcare Stocks: MannKind (MNKD), Disc Medicine (IRON)

TIPRANKS
·
Aug 06

Press Release: Labrador IRON ORE Royalty Corporation - Results for the Second Quarter ENDED JUNE 30, 2026

Dow Jones
·
Aug 06

Analysts’ Top Healthcare Picks: Tvardi Therapeutics (TVRD), Disc Medicine (IRON)

TIPRANKS
·
Jul 31

Disc Medicine Publishes Corporate Presentation on Hematology Pipeline Targeting Heme, Iron Pathways

Reuters
·
Jul 30

Disc Medicine Posts Smaller-than-expected Q2 Net Loss

Reuters
·
Jul 30

Disc Medicine Q2 EPS $(1.54) Beats $(1.77) Estimate

Benzinga Earnings
·
Jul 30

Disc Medicine Q2 Net Loss Widens to $59.53 Million; R&D Expenses Rise to $46.93 Million

Reuters
·
Jul 30

Disc Medicine - Ends Q2 2026 with $717.70 Mln in Cash and Securities; Runway into 2029

THOMSON REUTERS
·
Jul 30

Disc Medicine Q2 Net Income USD -59.532 Million VS. Ibes Estimate USD -68.2 Million

THOMSON REUTERS
·
Jul 30

Disc Medicine Q2 Basic EPS USD -1.54 VS. Ibes Estimate USD -1.75

THOMSON REUTERS
·
Jul 30